Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Phase II Study Of Neoadjuvant Pegylated Liposomal Doxorubicin And Cyclophosphamide ± Trastuzumab Followed By Docetaxel In Locally Advanced Breast Cancer

M. Tuxen, Soeren Cold, U. Tange, E. Balslev, D. Nielsen
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Wick W , Puduvalli VK , Chamberlain MC , van den Bent MJ , [14] Carpentier AF , Cher LM , et al . Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma . Expert Rev Anticancer Ther 2010 ; 28 : 1168 – 74 . Batchelor TT , Mulholland P , Neyns B , Nabors LB , [15] Campone M , Wick A , et al . Phase III randomized trial comparing the effi cacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma . J Clin Oncol 2013 ; 31 : 3212 – 8 . Thompson EM , Frenkel EP , Neuwelt EA . The paradoxical [16] effect of bevacizumab in the therapy of malignant gliomas . Neurology 2011 ; 76 : 87 – 93 . Verhoeff JJ , van Tellingen O , Claes A , Stalpers LJ , [17] van Linde ME , Richel DJ , et al . Concerns about antiangiogenic treatment in patients with glioblastoma multiforme . BMC Cancer 2009 ; 9 : 444 . Claes A , Wesseling P , Jeuken J , Maass C , Heerschap A , [18] Leenders WP . Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization . Mol Cancer Therapeut 2008 ; 7 : 71 – 8 . Van der Veldt AA , Lubberink M , Bahce I , Walraven M , de [19] Boer MP , Greuter HN , et al . Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs . Cancer Cell 2012 ; 21 : 82 – 91 . Reardon DA , Herndon JE , 2nd , Peters KB , Desjardins A , [20] Coan A , Lou E , et al . Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients . Br J Cancer 2012 ; 107 : 1481 – 7 . Reardon DA , Herndon JE , 2nd , Peters K , Desjardins A , [21] Coan A , Lou E , et al . Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients . J Neurooncol 2012 ; 107 : 213 – 21 . Wiestler B , Radbruch A , Osswald M , Combs SE , Jungk C , [22] Winkler F , et al . Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma . J Neurooncol 2014 ; 117 : 85 – 92 .
This paper references
10.1200/JCO.2010.31.9079
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
G. von Minckwitz (2011)
10.1200/JCO.2011.29.15_SUPPL.1028
Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.
G. von Minckwitz (2011)
10.1097/CAD.0b013e3283043585
Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
D. Rossi (2008)
10.1200/JCO.2005.06.156
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
T. Evans (2005)
10.1007/s00432-006-0079-7
Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
D. Aguiar Bujanda (2006)
10.1186/1471-2407-7-36
HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination
D. Tiezzi (2006)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1634/theoncologist.2008-0162
Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.
A. Berruti (2008)
10.1200/JCO.2005.03.8331
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
10.1097/01.CAD.0000236306.43209.2B
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
A. Rocca (2006)
10.1159/000318169
Phase II Trial in Japan of Sequential Administration of Weekly Paclitaxel Followed by FEC as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer [KBCSG0206 Trial: Kinki Breast Cancer Study Group (KBCSG)]
T. Taguchi (2010)
10.1200/JCO.1999.17.10.3033
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
K. Miller (1999)
10.1200/JCO.2003.05.135
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
P. Therasse (2003)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1245/s10434-011-2108-2
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
M. Kaufmann (2011)
10.1093/annonc/mdp263
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
C. Liedtke (2009)
10.1200/JCO.2005.04.1665
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
H. Bear (2006)
10.1016/S0140-6736(09)61964-4
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
L. Gianni (2010)
10.1200/JCO.2005.07.032
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
10.1200/JCO.1999.17.11.3412
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
A. Buzdar (1999)
10.1200/JCO.2007.10.9504
Ixabepilone and the narrow path to developing new cytotoxic drugs.
L. Gianni (2007)
10.1093/jnci/djs317
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
E. Bowles (2012)
10.1007/s10549-010-1027-4
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features
E. Montagna (2010)
10.1093/annonc/mdq751
Should liver metastases of breast cancer be biopsied to improve treatment choice?
G. Curigliano (2011)
10.1016/j.breast.2011.02.014
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer.
S. Dellapasqua (2011)
10.1016/0197-2456(89)90015-9
Optimal two-stage designs for phase II clinical trials.
R. Simon (1989)
10.1200/jco.2007.25.18_suppl.532
Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis
L. Gianni (2007)
10.1200/JCO.2011.37.2482
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
L. Lindström (2012)
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicentre phase II trial
G R Pond (2006)
Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
G. Artioli (2010)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1007/s00432-006-0079-7
Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
D. A. Bujanda (2006)
10.3816/CBC.2006.N.035
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
H. Kelly (2006)
GBG and AGO-B Study Groups
W Eiermann (2011)
10.1093/ANNONC/MDF284
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
H. Gogas (2002)



This paper is referenced by
10.1007/s00520-016-3256-5
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review
R. Fernandes (2016)
10.1631/jzus.B1600303
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice
M. Zhao (2017)
10.2147/BCTT.S170239
Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
Yesenia L Franco (2018)
10.7150/jca.24701
Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials
Y. Wu (2018)
Anticancer and cardioprotective effects of liposomal doxorubicin in the treatment of breast cancer
Yesenia L Franco (2018)
10.1080/1120009X.2020.1746886
Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II–III locally advanced breast cancer
J. Yao (2020)
10.1200/JCO.2015.33.15_SUPPL.E12086
BP-C1 in treatment of patients with stage IV breast cancer: A randomized, double-blind, placebo-controlled multicenter study and additional open-label treatment phase.
S. Larsén (2015)
10.1016/j.biotechadv.2015.10.002
Development of nanotheranostics against metastatic breast cancer--A focus on the biology & mechanistic approaches.
A. Subramanian (2015)
10.2147/BCTT.S71781
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase
S. Larsén (2014)
10.1155/2020/5729389
The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan
Chih-Chiang Hung (2020)
Breast Cancer: Targets and Therapy Dovepress
()
10.2147/TCRM.S176214
Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
Y. Wu (2018)
10.2147/BCTT.S179750
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
S. Antolín (2019)
Semantic Scholar Logo Some data provided by SemanticScholar